

In the Specification

At page 17, line 25, please delete the blank space and insert therefor, "HB-12195".

Please replace the Sequence Listing at pages 131-143 of the specification with the attached Substitute "Sequence Listing" pages 131-144, comprising SEQ ID NOS:1-18. Please renumber pages 144-153 of the specification as filed as pages 145-154.

In the Claims

Please add new Claims 53-67 as follows:

*✓* 53. An antibody having binding specificity for a mammalian chemokine receptor 3 protein or portion thereof, wherein the antibody can compete with monoclonal antibody 7B11 for binding to a human chemokine receptor 3 protein or portion thereof.

*✓* 54. An antigen binding fragment of the antibody of Claim 53.

*✓* 55. The antibody of Claim 53 wherein the antibody is 7B11.

*✓* 56. An antigen binding fragment of the antibody of Claim 55.

*✓* 57. A hybridoma which produces the antibody of Claim 53.

*✓* 58. The hybridoma of Claim 57 wherein the hybridoma is the 7B11 hybridoma.

*✓* 59. A method of inhibiting at least one function of a mammalian chemokine receptor 3 protein, comprising the step of contacting said protein with an antibody or antigen binding fragment thereof having binding specificity for a mammalian chemokine receptor 3 protein or portion thereof, wherein said antibody or fragment can compete with monoclonal antibody 7B11 for binding to a human chemokine receptor 3 protein or portion thereof.

60. The method of Claim 59 wherein the antibody or fragment thereof is 7B11 or an antigen binding fragment thereof.

61. A method for treating an inflammatory disease or condition, comprising administering to a mammal a therapeutically effective amount of an antibody or antigen binding fragment thereof having binding specificity for a mammalian chemokine receptor 3 protein or portion thereof, wherein said antibody or fragment can compete with monoclonal antibody 7B11 for binding to a human chemokine receptor 3 protein or portion thereof.

62. The method of Claim 61 wherein the antibody or fragment thereof is 7B11 or an antigen binding fragment thereof.

63. The method of Claim 61 wherein the inflammatory disease or condition is selected from the group consisting of an allergic disease or condition, autoimmune disease, and graft rejection.

64. The method of Claim 61 wherein the inflammatory disease or condition is asthma or allergic hypersensitivity.

65. A method of detecting or measuring human chemokine receptor 3 protein or a portion thereof on the surface of a cell, comprising contacting said cell with an antibody or antigen binding fragment thereof having binding specificity for a mammalian chemokine receptor 3 protein, wherein said antibody or fragment can compete with monoclonal antibody 7B11 for binding to a human chemokine receptor 3 protein.

66. The method of Claim 65 wherein the cell is a leukocyte.

67. The method of Claim 65 wherein the antibody or fragment thereof is 7B11 or an antigen binding fragment thereof.---